NCT02895750View on ClinicalTrials.gov

Efficacity and Safety of Metformin XR in CKD Stage 1 to 3

PHASE2CompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

August 30, 2017

Primary Completion Date

January 8, 2022

Study Completion Date

October 10, 2022

Conditions
Renal Insufficiency, Chronic
Interventions
DRUG

Metformin

Metformin extended release tablets (Glucophage 500 mg; 750 mg; 1,000 mg) administrated during 6 to 12 weeks (CKD1 and 3B, respectively)

Trial Locations (1)

80054

CHU Amiens Picardie, Amiens

All Listed Sponsors
lead

Centre Hospitalier Universitaire, Amiens

OTHER

NCT02895750 - Efficacity and Safety of Metformin XR in CKD Stage 1 to 3 | Biotech Hunter | Biotech Hunter